Key result
Low urotensin II receptor expression on preoperative biopsy was significantly associated with Gleason upgrading (OR 10.3) and pathology upstaging (OR 11.1) following radical prostatectomy.
Why the study?
Does low UTII-R expression on biopsy predict Gleason upgrading and pathology upstaging in prostate cancer patients?
Cohort (n=58)
Yes
Does low UTII-R expression on biopsy predict Gleason upgrading and pathology upstaging in prostate cancer patients?
Odds Ratio: 10.3 (95% CI 1.55–68.4)
p-value: p=0.01
Low UTII-R expression on preoperative biopsy is strongly associated with Gleason upgrading and pathology upstaging in prostate cancer patients.
May refine preoperative risk stratification in prostate cancer; hypothesis-generating and requires prospective validation.
AIM: A higher Gleason score was associated with a lower tumor urotensin II receptor (UTII-R) expression in prostate cancer patients. METHODS: A retrospective review of formalin-fixed paraffin-embedded tumor tissue derived from those who had prostatectomy and matching biopsy specimens was conducted at six Institutions. UTII-R expression was evaluated on biopsy by immunohistochemistry. RESULTS: A total of 58 subjects undergoing radical prostatectomy were included. At multivariate analysis, low UTII-R expression was a significant predictor of Gleason upgrading, with an odds ratio of 10.3 (95% CI: 1.55-68.4), and of pathology upstaging, with an odds ratio of 11.1 (95% CI: 1.23-100.48). CONCLUSIONS: UTII-R expression on biopsy was associated with Gleason upgrading and pathology upstaging in prostate cancer patients.
No takes yet. Share an insight, caveat, or question.
Cobelli et al. (2015) conducted a cohort in Prostate cancer (n=58). Low Urotensin II receptor (UTII-R) expression vs. High UTII-R expression was evaluated on Gleason upgrading (Gleason sum increase between biopsy and radical prostatectomy) (OR 10.3, 95% CI 1.55-68.4, p=0.01). Low urotensin II receptor expression on preoperative biopsy was significantly associated with Gleason upgrading (OR 10.3) and pathology upstaging (OR 11.1) following radical prostatectomy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: